Detectable MRD Is Prognostic of Poor HCT Outcomes in Adult ALL
February 16th 2023Risk of relapse was significantly greater for those with acute lymphoblastic leukemia who had low minimal residual disease of less than 10-4 vs those with undetectable MRD, according to results of a retrospective study.
Read More
Zamtocabtagene Autoleucel Shows High Response Rates in Relapsed/Refractory DLBCL
February 16th 2023Findings from the phase 2 DALY II USA trial showed that the 28-day objective response rate was 78% with freshly administered zamtocabtagene autoleucel, exceeding the prespecified efficacy threshold for interim analysis.
Read More
Precision Oncology Inches into Head and Neck Cancer Paradigm
February 4th 2023In an interview with Targeted Oncology, Everett E. Vokes, MD, discussed precision oncology for head and neck cancer and how the molecular biology of head and neck cancers is an opportunity for new investigations and treatment development.
Read More
Engaging Oncology Peers in Discussions Around Precision Medicine
February 3rd 2023In an interview with Targeted Oncology™, Manmeet Ahluwalia, MD, discussed the importance of the Inaugural Miami Cancer Institute Precision Medicine Oncology Symposium, what to expect from his presentation on brain metastases, and what to expect from presentations by other experts.
Read More
brPROPHET May Better Detect ctDNA and Identify MRD in Colorectal Cancer
January 23rd 2023According to initial data presented at the 2023 Gastrointestinal Cancers Symposium, the novel, personalized, tumor-informed brPROPHET technology was more sensitive in detecting molecular residual disease vs other assays.
Read More
ctDNA Serves as Biomarker for Early Response Assessment in Advanced CRC
January 23rd 2023Compared with other tumor biomarkers, circulating tumor DNA may be ideal for early response assessment and have potential to enable use of adaptive clinical study designs in the future for patients with advanced colorectal cancer.
Read More
Adding Bevacizumab to Trifluridine/Tipiracil Boosts Survival, Disease Control Rate in mCRC
January 21st 2023The SUNLIGHT study is the first phase 3 study in the setting of refractory metastatic colorectal cancer to demonstrate an improvement in overall survival vs an active control, according to Josep Tabernero, MD, PhD.
Read More
Sorafenib in Combination with SBRT Extends Survival in Locally Advanced HCC
January 21st 2023The phase 3 NRG/RTOG 1112 adds to the body of evidence for the role of external beam radiation, bringing SBRT to the armamentarium of treatment for patients with locally advanced hepatocelluar carcinoma, according to Laura Dawson, MD, FRCPC.
Read More
Early Trial Results Show Promise for Combination of Lenvatinib, TACE, and Microwave Ablation in HCC
January 20th 2023Results from the phase 2 Talem trial, presented at the 2023 Gastrointestinal Cancers Symposium, showed the promising signs of efficacy, anti-tumor activity, and tolerable adverse events when combining blank-microsphere transarterial chemoembolization with lenvatinib and sequential microwave ablation for patients with HCC.
Read More
Addition of Pembrolizumab to Lenvatinib for HCC Elicits Similar Scores in LEAP-002
January 20th 2023Data from the health-related quality of life analysis of the LEAP-002 study showed similar scores with the addition of pembrolizumab to lenvatinib vs placebo plus lenvatinib in patients with hepatocellular carcinoma.
Read More
Lenvatinib Elicits Survival Benefit After Progression on Immunotherapy in HCC
January 20th 2023Patients with advanced hepatocellular carcinoma who were treated with lenvatinib following progression on immunotherapy had a median overall survival of 12.8 months and progression-free survival of 3.7 months.
Read More